Key result
PAI-1 dose-dependently promotes endothelial microparticle release, driving increased thrombin generation in vitro.
Why the study?
The role of PAI-1 in promoting endothelial microparticles formation and its link to thrombosis through endothelial dysfunction was not established.
PAI-1 promotes the formation of procoagulant endothelial microparticles, providing a potential mechanistic link between endothelial dysfunction and thrombosis.
May link PAI-1 to thrombosis via microparticles; hypothesis-generating and requires in vivo confirmation before clinical consideration.
The data disclose a novel effect of PAI-1 to dose-dependently promote formation of endothelial microparticles with the reduced transmembrane asymmetry of phospholipids. This phenomenon may be responsible for the observed increase in in vitro thrombin generation. These findings could potentially link these hallmarks of endothelial dysfunction-elevated levels of PAI-1 and propensity toward thrombosis.
No takes yet. Share an insight, caveat, or question.
Brodsky et al. (2002) studied Endothelial dysfunction and thrombosis. Plasminogen Activator Inhibitor-1 (PAI-1) was evaluated on Formation of endothelial microparticles and in vitro thrombin generation. Plasminogen Activator Inhibitor-1 dose-dependently promotes the formation of endothelial microparticles, increasing in vitro thrombin generation and potentially linking PAI-1 to thrombosis.
Synapse has enriched 5 related papers. Consider them for comparative context: